European journal of radiology · 2025
Cost effectiveness of digital breast tomosynthesis for breast cancer screening in a Swedish setting.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fridhammar Adam, Johnson Kristin, Rosso Aldana, Andersson Emelie, Andersson Ingvar, Lång Kristina, Borgquist Signe, Carlsson Katarina Steen, Zackrisson Sophia
Аннотация
BACKGROUND: In the Malmö Breast Tomosynthesis Screening Trial (MBTST), digital breast tomosynthesis (DBT) increased the detection rate of breast cancer compared to currently used digital mammography (DM). This study evaluated the cost effectiveness of DBT versus DM in Sweden using data from MBTST.
MATERIALS AND METHOD: A health economic model was used to compare a breast cancer screening programme using DBT to breast cancer screening using DM in women aged 40-74. Model input values on demographics, breast cancer incidence and mortality were derived from regional registries. The effect of DBT on detection rates and interval breast cancer was based on MBTST. Key information is not yet available and scenario analyses were used to explore the reduction in relative breast cancer mortality required to meet willingness-to-pay thresholds between €10,000 and €50,000/quality-adjusted life year (QALY), assuming three levels of DBT examination cost.
RESULTS: Compared with DM, DBT-screening was estimated to detect 56 more invasive cancers and 18 fewer interval cancers per 100,000 invited women. The relative reduction in breast cancer mortality for DBT to be cost effective varied between 2.3 and 14.2% for the lowest versus highest evaluated cost and willingness-to-pay scenarios. The required reduction at a DBT cost and willingness-to-pay threshold of €61 and €50,000/QALY respectively was 3.6%.
CONCLUSION: This model analysis shows that the cost effectiveness of DBT-screening is dependent on the expected relative reduction in breast cancer mortality and the willingness-to-pay for screening. Furthermore, the results are driven by the future costs for DBT-screening examinations.
MATERIALS AND METHOD: A health economic model was used to compare a breast cancer screening programme using DBT to breast cancer screening using DM in women aged 40-74. Model input values on demographics, breast cancer incidence and mortality were derived from regional registries. The effect of DBT on detection rates and interval breast cancer was based on MBTST. Key information is not yet available and scenario analyses were used to explore the reduction in relative breast cancer mortality required to meet willingness-to-pay thresholds between €10,000 and €50,000/quality-adjusted life year (QALY), assuming three levels of DBT examination cost.
RESULTS: Compared with DM, DBT-screening was estimated to detect 56 more invasive cancers and 18 fewer interval cancers per 100,000 invited women. The relative reduction in breast cancer mortality for DBT to be cost effective varied between 2.3 and 14.2% for the lowest versus highest evaluated cost and willingness-to-pay scenarios. The required reduction at a DBT cost and willingness-to-pay threshold of €61 and €50,000/QALY respectively was 3.6%.
CONCLUSION: This model analysis shows that the cost effectiveness of DBT-screening is dependent on the expected relative reduction in breast cancer mortality and the willingness-to-pay for screening. Furthermore, the results are driven by the future costs for DBT-screening examinations.